Is the increase in osteoporosis prevention a result of the audit?

Clinical Neurology and Neurosurgery

Volumn 108, Issue 7, 2006, Pages 718-719

  Naunton, Mark ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Audit; Bisphosphonate; Corticosteroids; Osteoporosis; Prevention

Indexed keywords

ALENDRONIC ACID; CALCIUM; CORTICOSTEROID; ETIDRONIC ACID; RISEDRONIC ACID; VITAMIN D;

HEALTH CARE DELIVERY; HIGH RISK POPULATION; HUMAN; LETTER; OSTEOPOROSIS; UNITED KINGDOM;

ADRENAL CORTEX HORMONES; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; ETIDRONIC ACID; GREAT BRITAIN; HUMANS; MEDICAL AUDIT; NEUROLOGY; OSTEOPOROSIS; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; VITAMIN D;

EID: 33748800476     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2006.02.004     Document Type: Letter

References (2)

1. Lozsadi D.A., Peters G., Sadik H.Y., Kellett M.W., Fox S.H., and Smith D.F. Prevention of osteoporosis in glucocorticoid-treated neurology patients. Clin Neurol Neurosurg 108 (2006) 157-162
2. National guidelines for the prevention and management of corticosteroid-induced osteoporosis. Bath: UK Osteoporosis Consensus Group; 1998.